Contactin-Associated Protein-2 (CASPR2) Antibody, IgG by CBA-IFA With Reflex to Titer, CSF
Also known as: CASPR2GCSF
Use
Aids in diagnosis of contactin-associated protein-2 (CASPR2) antibody disorders associated with acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. This test is used to manage antibody-positive (CASPR2) individuals following immunotherapy and/or plasmapheresis. The test detects the CASPR2 IgG antibody, which may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies. The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, and potentially with tumors such as thymoma and small cell lung cancer.
Special Instructions
Serum is the preferred specimen; refer to Contactin-Associated Protein-2 Antibody, IgG CBA-IFA with Reflex to Titer, Serum (2009452). If CASPR2 antibody IgG is positive, then CASPR2 antibody IgG titer will be added. Additional charges apply.
Limitations
The presence of CASPR2 IgG antibody is associated with a spectrum of clinical disorders and tumors, but the full spectrum continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings. This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the FDA, but is intended for clinical purposes.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
LOINC Codes
- 90820-2
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
0.5 mL
Minimum Volume
0.15 mL
Container
ARUP standard transport tube
Causes for Rejection
Contaminated, hemolyzed, or severely lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month |